5AM Venture Management’s Janux Therapeutics JANX Stock Holding History

5AM Venture Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-446,266	Closed	-$5.88M	–	25
2022 Q4	$5.88M	Hold	446,266	–	–	1.58%	18
2022 Q3	$6.04M	Hold	446,266	–	–	1.16%	17
2022 Q2	$5.45M	Hold	446,266	–	–	1.35%	17
2022 Q1	$6.4M	Hold	446,266	–	–	1.4%	15
2021 Q4	$8.8M	Hold	446,266	–	–	1.65%	14
2021 Q3	$9.65M	Hold	446,266	–	–	1.96%	13
2021 Q2	$11.1M	Buy	+446,266	New	+$9.94M	2.8%	10

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

5AM Venture Management's JANX Position: Q1 2023 in Review

5AM Venture Management sold out of Janux Therapeutics (JANX) in Q1 2023, closing a stake of 446,266 shares — an estimated $5.88M sold.

5AM Venture Management first reported a position in JANX in Q2 2021 and held it in 7 quarters. The position peaked at $11.1M in Q2 2021. 48 funds tracked by Wall St. Rank hold JANX as of Q1 2023.

5AM Venture Management reported no remaining Janux Therapeutics position as of Q1 2023 after selling out during the quarter.
5AM Venture Management sold 446,266 Janux Therapeutics shares in Q1 2023, an estimated $5.88M.
5AM Venture Management first reported a position in Janux Therapeutics in Q2 2021 and held it in 7 quarters.
5AM Venture Management's Janux Therapeutics position peaked at $11.1M in Q2 2021.
48 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2023.

Based on 5AM Venture Management's 13F filing for Q1 2023, filed 15 May 2023.